Abstract | BACKGROUND: AIM: METHODS: RESULTS: Nine of the 10 patients achieved clinical remission within 8 weeks. At 24 weeks, seven patients were in clinical remission. Marked improvement in the Ulcerative Colitis Symptom Score was seen by 1 week (P = 0.004) and on rectal biopsy and Inflammatory Bowel Disease Questionnaire by 2 weeks (both P < 0.05). Improvements persisted to 24 weeks ( Ulcerative Colitis Symptom Score, Inflammatory Bowel Disease Questionnaire, both P < 0.005). Eight of the nine responders relapsed (median, 9 weeks), but remission was re-achieved with further corticosteroids and the addition of azathioprine. At 24 weeks, seven patients were in full clinical remission, five off all steroid therapy. In vitro measurement of lymphocyte steroid sensitivity demonstrated steroid resistance in 22% of subjects. All were rendered steroid sensitive in the presence of basiliximab. CONCLUSIONS:
|
Authors | T J Creed, M R Norman, C S J Probert, R F Harvey, I S Shaw, J Smithson, J Anderson, M Moorghen, J Gupta, N A Shepherd, C M Dayan, S D Hearing |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 18
Issue 1
Pg. 65-75
(Jul 01 2003)
ISSN: 0269-2813 [Print] England |
PMID | 12848627
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Drug Combinations
- Immunosuppressive Agents
- Recombinant Fusion Proteins
- Steroids
- Basiliximab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal
(therapeutic use)
- Basiliximab
- Colitis, Ulcerative
(drug therapy)
- Drug Combinations
- Drug Resistance
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Recombinant Fusion Proteins
- Remission Induction
- Steroids
(therapeutic use)
- Treatment Outcome
|